TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16573817

Group type: EXPERIMENTAL
Intervention: Negative expiratory pressure (NEP) -5 cmH2O in supine position
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Negative expiratory pressure (NEP) -5 cmH2O in seated position
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Negative expiratory pressure (NEP) -7 cmH2O
Number of subjects: 55
Study: 15101023

Group type: EXPERIMENTAL
Intervention: Nesiritide
Number of subjects: 61

Group type: COMPARATOR
Intervention: NTG
Number of subjects: 61
Study: 11779610

Group type: EXPERIMENTAL
Intervention: Lipiodol
Number of subjects: 34

Group type: COMPARATOR
Intervention: Expectant management (no treatment)
Number of subjects: 34
Study: 9751000

Group type: EXPERIMENTAL
Intervention: Cocaine cue sessions
Number of subjects: 69

Group type: COMPARATOR
Intervention: Non-drug events
Number of subjects: 69
Study: 7545059

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 2528862

Group type: EXPERIMENTAL
Intervention: Merck vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pasteur vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: CLB vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Korean vaccine
Number of subjects: 0
Study: 29956648

Group type: EXPERIMENTAL
Intervention: New N-acetylcysteine 2% oral solution
Number of subjects: 46

Group type: COMPARATOR
Intervention: Reference N-acetylcysteine 2% oral solution
Number of subjects: 46
Study: 30711316

Group type: EXPERIMENTAL
Intervention: Adjuvanted recombinant zoster vaccine co-administered with the 23-valent pneumococcal polysaccharide vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 28257217

Group type: EXPERIMENTAL
Intervention: Peak LC Bond (G1)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Clearfil Protect Bond (G2)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Clearfil Protect Bond with prior selective acid etching (G3)
Number of subjects: 90
Study: 26241460

Group type: EXPERIMENTAL
Intervention: Mandibular Advancement Device (MAD)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo Device (PD)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: MAD
Number of subjects: 42

Group type: COMPARATOR
Intervention: PD
Number of subjects: 42
Study: 23998148

Group type: EXPERIMENTAL
Intervention: Arrangement using adhesive paper teeth
Number of subjects: 123

Group type: COMPARATOR
Intervention: Traditional standard care selection and arrangement of anterior teeth
Number of subjects: 123
Study: 22122821

Group type: EXPERIMENTAL
Intervention: Xeldrin®20 (test product)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Losec®20 (reference product)
Number of subjects: 24
Study: 19369174

Group type: EXPERIMENTAL
Intervention: RotaTeq (pentavalent rotavirus vaccine), three oral doses
Number of subjects: 189

Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 189
Study: 16461781

Group type: EXPERIMENTAL
Intervention: Wide excision with margins ≥ 1 cm
Number of subjects: 158
Study: 15148646

Group type: EXPERIMENTAL
Intervention: Anterior levatorplasty
Number of subjects: 54

Group type: COMPARATOR
Intervention: Internal sphincterotomy
Number of subjects: 54
Study: 11208686

Group type: EXPERIMENTAL
Intervention: Genistein (10 to 300 nmol/min for 6 minutes)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 17beta-estradiol (equimolar concentrations)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Genistein
Number of subjects: 15

Group type: COMPARATOR
Intervention: N:(G)‐monomethyl‐L‐arginine (NO synthase inhibitor)
Number of subjects: 15
Study: 9409357

Group type: EXPERIMENTAL
Intervention: rhIGF‐I (0.10 mg/kg/day)
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: rhIGF‐I (0.05 mg/kg/day)
Number of subjects: 266

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 266
Study: 8108538

Group type: EXPERIMENTAL
Intervention: Intra-articular steroids
Number of subjects: 111

Group type: COMPARATOR
Intervention: Non-steroidal anti-inflammatory drugs (NSAIDs)
Number of subjects: 111
Study: 3653529

Group type: EXPERIMENTAL
Intervention: Cisapride 10 mg p.o. 3 times/day for 4 days and 10 mg 1.5 h before investigation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 0
Study: 31797532

Group type: EXPERIMENTAL
Intervention: 1-month duration of dual antiplatelet therapy (DAPT) after elective drug-coated balloon angioplasty
Number of subjects: 303
Study: 29954759

Group type: EXPERIMENTAL
Intervention: Marinated beef
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-marinated beef
Number of subjects: 0
Study: 29325367

Group type: EXPERIMENTAL
Intervention: Aerobic exercise combined with resistance training for 12 weeks
Number of subjects: 73

Group type: COMPARATOR
Intervention: Conventional medical treatment and health education
Number of subjects: 73
Study: 26257511

Group type: EXPERIMENTAL
Intervention: HCP1004 (naproxen 500 mg and esomeprazole strontium 20 mg)
Number of subjects: 70

Group type: COMPARATOR
Intervention: VIMOVO® (naproxen 500 mg and esomeprazole magnesium 20 mg)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Comparison of HCP1004 to VIMOVO®
Number of subjects: 70
Study: 23392414

Group type: EXPERIMENTAL
Intervention: Xclose Tissue Repair System (Anulex Technologies, Minnetonka, MN) for anular repair
Number of subjects: 750

Group type: COMPARATOR
Intervention: Discectomy without anular repair
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: Xclose Tissue Repair System
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: Xclose Tissue Repair System and Discectomy without anular repair
Number of subjects: 750
Study: 20491152

Group type: EXPERIMENTAL
Intervention: Insole Group (IG) - wore MedReflex shoe insoles during everyday life and training sessions
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Training Group (TG) - completed the same training program without insoles
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control Group (CG) - no exercise
Number of subjects: 28
Study: 18181880

Group type: EXPERIMENTAL
Intervention: Inner speech
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Visual coding
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control stimuli
Number of subjects: 45
Study: 16644437

Group type: EXPERIMENTAL
Intervention: Exercise echocardiography with HCU device (EchoCG-HCU)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Exercise electrocardiography (ECG)
Number of subjects: 58
Study: 12673180

Group type: EXPERIMENTAL
Intervention: Isometric exercise (handgrip at 75% of maximal strength for up to 5 minutes) in HCM patients
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control subjects (no intervention)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Isometric exercise (handgrip at 75% of maximal strength for up to 5 minutes) in obstructive HCM patients
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Isometric exercise (handgrip at 75% of maximal strength for up to 5 minutes) in nonobstructive HCM patients
Number of subjects: 46
Study: 11099371

Group type: EXPERIMENTAL
Intervention: Siberian ginseng (ES) 1,200 mg/day
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Siberian ginseng (ES)
Number of subjects: 9
Study: 8615502

Group type: EXPERIMENTAL
Intervention: Mild intraoperative hypothermia
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intraoperative core temperature
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: In vitro temperature manipulations
Number of subjects: 10

Group type: COMPARATOR
Intervention: Intraoperative hypothermia
Number of subjects: 10
Study: 1727915

Group type: EXPERIMENTAL
Intervention: Pamidronate disodium (APD) 60 mg as a single 24-hour infusion
Number of subjects: 65

Group type: COMPARATOR
Intervention: Etidronate disodium (EHDP) 7.5 mg/kg given as a 2-hour infusion daily for 3 days
Number of subjects: 65
Study: 6379455

Group type: EXPERIMENTAL
Intervention: tranexamic acid
Number of subjects: 479

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 479
Study: 29603286

Group type: EXPERIMENTAL
Intervention: Lettuce (300 g with 30 mL mayonnaise)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Rhubarb (300 g with 60 mL lactose free cream)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Bread (2 slices with 10 g butter)
Number of subjects: 15
Study: 26780969

Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation for 12 months
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group without supplementation
Number of subjects: 45
Study: 24428461

Group type: EXPERIMENTAL
Intervention: Intensive quitline support in combination with tailored supplementary materials
Number of subjects: 512

Group type: COMPARATOR
Intervention: Standard self-help brochure
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Intensive quitline support
Number of subjects: 512
Study: 22905896

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Number of subjects: 89

Group type: COMPARATOR
Intervention: spirit‐only MI (SOMI)
Number of subjects: 89

Group type: COMPARATOR
Intervention: self‐change (SC)
Number of subjects: 89
Study: 20446817

Group type: EXPERIMENTAL
Intervention: Group A: output voltage increased from 25% to 35% to 45% with 800 shocks per voltage
Number of subjects: 62

Group type: COMPARATOR
Intervention: Group B: constant output voltage of 35%
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Group C: output voltage decreased from 45% to 35% to 25%
Number of subjects: 62
Study: 18018469

Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg daily for six months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40
Study: 16122593

Group type: EXPERIMENTAL
Intervention: Centric splint
Number of subjects: 74

Group type: COMPARATOR
Intervention: Distraction splint
Number of subjects: 74
Study: 12373624

Group type: EXPERIMENTAL
Intervention: High phenol olive oil (70 grams per day)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Low phenol olive oil (70 grams per day)
Number of subjects: 25
Study: 11257952

Group type: EXPERIMENTAL
Intervention: 0.0625% bupivacaine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.125% bupivacaine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine
Number of subjects: 60
Study: 9247511

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 244

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 244
Study: 8102430

Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) 2.7 g daily for 6 weeks
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 3770031

Group type: EXPERIMENTAL
Intervention: Carminomycin (CMM) 20 mg/m2
Number of subjects: 64

Group type: COMPARATOR
Intervention: Doxorubicin (DOX) 75 mg/m2
Number of subjects: 64
Study: 29978276

Group type: EXPERIMENTAL
Intervention: Electrical Stimulation (ES) guidance for BoNT A injection
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ultrasonography (USG) guidance for BoNT A injection
Number of subjects: 40
Study: 29852286

Group type: EXPERIMENTAL
Intervention: Hybrid training system (HTS)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Isokinetic dynamometer (control)
Number of subjects: 42
Study: 26762150

Group type: EXPERIMENTAL
Intervention: Patient Decision Aid (PDA)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 225
Study: 25701140

Group type: EXPERIMENTAL
Intervention: Pharmacological intervention (250 μg of recombinant hCG)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Mechanical intervention (aspiration of dominant and subordinate follicles ≥10 mm)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (150 IU/day of recombinant follicle-stimulating hormone starting on menstrual cycle day 3)
Number of subjects: 16
Study: 23877348

Group type: EXPERIMENTAL
Intervention: lactulose plus rifaximin 1,200 mg/day
Number of subjects: 120

Group type: COMPARATOR
Intervention: lactulose (placebo)
Number of subjects: 120
Study: 20608027

Group type: EXPERIMENTAL
Intervention: Natriuretic peptide indices and oxidative stress assessment in CHF patients
Number of subjects: 52
Study: 18184031

Group type: EXPERIMENTAL
Intervention: Telephone self-report of medication use
Number of subjects: 566
Study: 16494641

Group type: EXPERIMENTAL
Intervention: Sodium alginate (SA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 0
Study: 14583362

Group type: EXPERIMENTAL
Intervention: Bail-out abciximab
Number of subjects: 1030

Group type: COMPARATOR
Intervention: Routine upfront abciximab
Number of subjects: 1030
Study: 11082370

Group type: EXPERIMENTAL
Intervention: Full sternotomy approach plus CPB (group A)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Full sternotomy off-pump (group B)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Limited left anterior thoracotomy off-pump (group C)
Number of subjects: 30
Study: 8828546

Group type: EXPERIMENTAL
Intervention: NSAID drug challenge
Number of subjects: 240
Study: 1447640

Group type: EXPERIMENTAL
Intervention: Partially hydrolyzed formula
Number of subjects: 205

Group type: COMPARATOR
Intervention: Intact whey‐predominant milk protein formula (Control)
Number of subjects: 205
Study: 29901705

Group type: EXPERIMENTAL
Intervention: Rituximab as first-line treatment
Number of subjects: 290

Group type: COMPARATOR
Intervention: Watchful waiting (control)
Number of subjects: 290
Study: 27267755

Group type: EXPERIMENTAL
Intervention: Self-management and exercise program (PLE(2)NO)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Educational intervention (control program)
Number of subjects: 0
Study: 25129064

Group type: EXPERIMENTAL
Intervention: Vorapaxar
Number of subjects: 7479

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7479
Study: 23672463

Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg
Number of subjects: 21
Study: 20159311

Group type: EXPERIMENTAL
Intervention: Injectable poly-L-lactic acid (PLLA)
Number of subjects: 233

Group type: COMPARATOR
Intervention: Human-derived collagen
Number of subjects: 233
Study: 18242934

Group type: EXPERIMENTAL
Intervention: Nursing care (self-efficacy promotion and medical treatment of vascular risk factors)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 153
Study: 15908388

Group type: EXPERIMENTAL
Intervention: ICC‐1132/ISA 720 (20 mug)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ICC‐1132/ISA 720 (50 mug)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ICC‐1132/ISA 720
Number of subjects: 0
Study: 12825333

Group type: EXPERIMENTAL
Intervention: Combined protocol (5 min rest and 5 min self‐selected active recovery)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Rest protocol (10 min rest in a sitting position)
Number of subjects: 12
Study: 10813106

Group type: EXPERIMENTAL
Intervention: Laparoscopic ovarian electrocautery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gonadotropin ovulation induction
Number of subjects: 0
Study: 9121810

Group type: COMPARATOR
Intervention: Morphine plus placebo (M + P)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Morphine plus nimodipine (M + N)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Morphine only (M)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Nimodipine (30 mg every 8 h)
Number of subjects: 32
Study: 1504891

Group type: EXPERIMENTAL
Intervention: Fenoterol 10 micrograms
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Fenoterol 200 micrograms
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 6237209

Group type: EXPERIMENTAL
Intervention: Seeded Dacron grafts
Number of subjects: 161

Group type: COMPARATOR
Intervention: Unseeded Dacron grafts
Number of subjects: 161

Group type: COMPARATOR
Intervention: Vein grafts
Number of subjects: 161
Study: 31236471

Group type: EXPERIMENTAL
Intervention: Head-Up Sleep (HUS) at greater than 45°
Number of subjects: 88

Group type: COMPARATOR
Intervention: Head-Down Sleep (HDS)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Head-Up Sleep (HUS)
Number of subjects: 88
Study: 30372482

Group type: EXPERIMENTAL
Intervention: SER (50 to 200 mg/d) + GCBT
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: SER + GPT
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: SER + GCBT
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: SER
Number of subjects: 147

Group type: COMPARATOR
Intervention: GCBT
Number of subjects: 147
Study: 26540600

Group type: EXPERIMENTAL
Intervention: Needle acupuncture
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Laser acupuncture
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sham needle acupuncture
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sham laser acupuncture
Number of subjects: 60

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 60
Study: 23955660

Group type: EXPERIMENTAL
Intervention: Pharmaceutical care (PC) intervention
Number of subjects: 332

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Age <40 years
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Male gender
Number of subjects: 332
Study: 22945620

Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT) for depression, 16 to 20 sessions
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 49
Study: 19757052

Group type: EXPERIMENTAL
Intervention: Comprehensive implementation support for teachers
Number of subjects: 2983

Group type: EXPERIMENTAL
Intervention: Regular workshop training only
Number of subjects: 2983

Group type: COMPARATOR
Intervention: Standard care control
Number of subjects: 2983
Study: 16512088

Group type: EXPERIMENTAL
Intervention: 180 mg of red vine leaf extract AS 195 twice daily (360 mg in total) for six weeks
Number of subjects: 39
Study: 12780674

Group type: EXPERIMENTAL
Intervention: Low-dose tacrolimus (blood concentration 5-10 ng/mL) with MMF and low-dose corticosteroid (stopped after 5 months) and induction with daclizumab
Number of subjects: 82

Group type: COMPARATOR
Intervention: Standard-dose tacrolimus (blood concentration 10-15 ng/mL) with MMF and standard dose corticosteroid
Number of subjects: 82
Study: 10692620

Group type: EXPERIMENTAL
Intervention: morphine sulphate 10 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: lorazepam 0.5 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: dextropropoxyphene napsylate 100 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study: 9355703

Group type: EXPERIMENTAL
Intervention: Gestational diabetes erythrocytes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (non-diabetic pregnant women) erythrocytes
Number of subjects: 0
Study: 8223138

Group type: COMPARATOR
Intervention: 60 mg levodropropizine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 60 mg dropropizine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 120 mg levodropropizine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 120 mg dropropizine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 4036849

Group type: EXPERIMENTAL
Intervention: Vitamin D2 supplementation (15,000 IU weekly)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study: 31640645

Group type: EXPERIMENTAL
Intervention: OPAL intervention (community-based, multi-setting, multi-strategy)
Number of subjects: 2611

Group type: COMPARATOR
Intervention: Matched comparison communities (COMP)
Number of subjects: 2611

Group type: EXPERIMENTAL
Intervention: OPAL intervention
Number of subjects: 2611
Study: 28208190

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 3712

Group type: COMPARATOR
Intervention: Other atypicals
Number of subjects: 3712

Group type: COMPARATOR
Intervention: Typical antipsychotics
Number of subjects: 3712
Study: 25872943

Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment (OMT) applied to the study group, once a week for the entire period of hospitalization.
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sham treatment ('soft touch') applied to the sham group, once a week for the entire period of hospitalization.
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group receiving standard medical care only, no additional treatment.
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: All groups (study, sham, control)
Number of subjects: 120
Study: 23531118

Group type: EXPERIMENTAL
Intervention: Alogliptin 25 mg once daily
Number of subjects: 441

Group type: COMPARATOR
Intervention: Glipizide 5 mg once daily (titrated to 10 mg if needed)
Number of subjects: 441
Study: 21377716

Group type: EXPERIMENTAL
Intervention: Combination of fluticasone furoate and oxymetazoline
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oxymetazoline alone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 60
Study: 20004289

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 12

Group type: COMPARATOR
Intervention: Citalopram
Number of subjects: 12

Group type: COMPARATOR
Intervention: Paroxetine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Duloxetine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sertraline
Number of subjects: 12

Group type: COMPARATOR
Intervention: Venlafaxine
Number of subjects: 12
Study: 17251259

Group type: EXPERIMENTAL
Intervention: Baseline mitral regurgitation (MR) severity
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: Moderate-severe MR
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: Progression of MR during the first post-MI month
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: Progression of MR over 20 months in survivors
Number of subjects: 496
Study: 15159698

Group type: EXPERIMENTAL
Intervention: IL-1 beta concentration in CSF (Days 8-15 after SAH)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IL-6 concentration in CSF (Days 0-3 after SAH)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Patients without vasospasm and neurological deficits
Number of subjects: 0
Study: 12530483

Group type: EXPERIMENTAL
Intervention: Suppressive oral acyclovir 400 mg three times daily
Number of subjects: 234

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 234